By Justin · Tuesday, April 13th, 2010
Provectus Pharmaceuticals, Inc. (PVCT), which develops cancer treatments in the same industry as companies like Genta Incorporated (GETA) and Dendreon Corporation (DNDN), continues to receive positive press regarding its Rose Bengal-based treatment for metastatic melanoma.
Provectus Pharmaceuticals, Inc. (PVCT), which is developing a cancer treatment based on the Rose Bengal compound, continues to receive positive press highlighting the effectiveness and promise of its new PV-10 drug for the treatment of metastatic melanoma.
An article in ScienceDirect, entitled “New era in metastatic melanoma,” highlights the company’s phase II PV-10 trials, which stimulated “intrigue and interest” among delegates at the 3rd World Meeting of Interdisciplinary Melanoma/Skin Cancer Centres.
Of particular note, according to Dr. Agarwala, a principal investigator in the Phase II study, has been the “by-stander effect” where the agent also elicits spontaneous regression of nearby melanoma tumors that have not been injected.
Follow-up survival data from the Phase II study for the first 20 subjects showed that patients who were responsive had a mean overall survival rate of 11.8 months, compared to 9.9 months for those who did not achieve a robust response. Furthermore, two of five subjects displayed the by-stander effects with regression of visceral or nodal metastases that had not been injected.
“In melanoma the overall effect appears similar to that of recent melanoma vaccines with the important additional features that PV-10 reduces overall disease burden by destroying the injected lesion,” said Eric Wachter, who was quoted in the article. “The process occurs insitu so the patient’s specific melanoma antigens are presented in the proper immunologic context.”
While PV-10 is unlikely to play a role in patients with widespread organ involvement, Agarwala believes it offers the possibility to intervene early in the metastatic process, according to the article.
theotcinvestor.com/...port-highlights-effectiveness-of-pv-10/#
Keine Kauf- oder Verkaufsempfehlung.
Jeder ist sich selbst der nächste.
Viel Erfolg euch allen...